Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Experimental & Clinical Cancer Research
Published in: Journal of Experimental & Clinical Cancer Research 1/2010

Open Access 01-12-2010 | Research

Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation

Authors: Long Wu, Chun-Wei Peng, Jin-Xuan Hou, Yan-Hua Zhang, Chuang Chen, Liang-Dong Chen, Yan Li

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2010

Login to get access

Abstract

Background

To better search for potential markers for hepatocellular carcinoma (HCC) invasion and metastasis, proteomic approach was applied to identify potential metastasis biomarkers associated with HCC.

Methods

Membrane proteins were extracted from MHCC97L and HCCLM9 cells, with a similar genetic background and remarkably different metastasis potential, and compared by SDS-PAGE and identified by ESI-MS/MS. The results were further validated by western blot analysis, immunohistochemistry (IHC) of tumor tissues from HCCLM9- and MHCC97L-nude mice, and clinical specimens.

Results

Membrane proteins were extracted from MHCC97L and HCCLM9 cell and compared by SDS-PAGE analyses. A total of 14 differentially expressed proteins were identified by ESI-MS/MS. Coronin-1C, a promising candidate, was found to be overexpressed in HCCLM9 cells as compared with MHCC97L cells, and validated by western blot and IHC from both nude mice tumor tissues and clinical specimens. Coronin-1C level showed an abrupt upsurge when pulmonary metastasis occurred. Increasing coronin-1C expression was found in liver cancer tissues of HCCLM9-nude mice with spontaneous pulmonary metastasis. IHC study on human HCC specimens revealed that more patients in the higher coronin-1C group had overt larger tumor and more advanced stage.

Conclusions

Coronin-1C could be a candidate biomarker to predict HCC invasive behavior.
Appendix
Available only for authorised users
Literature
1.
Parkin DM, Bray F, Ferlay J, Pisani P: Global Cancer Statistics, 2002. CA Cancer J Clin. 2005, 55: 74-108. 10.3322/canjclin.55.2.74.CrossRef
2.
Sell S: Mouse Models to Study the Interaction of Risk Factors for Human Liver Cancer. Cancer Res. 2003, 63: 7553-7562.
3.
Tang ZY, Ye SL, Liu YK, Qin LX, Sun HC, Ye QH, Wang L, Zhou J, Qiu SJ, Li Y, Ji XN, Liu H, Xia JL, Wu ZQ, Fan J, Ma ZC, Zhou XD, Lin ZY, Liu KD: A decade's studies on metastasis of hepatocellular carcinoma. J Cancer Res Clin Oncol. 2004, 130: 187-196. 10.1007/s00432-003-0511-1.CrossRef
4.
El Serag HB: Hepatocellular carcinoma: recent trends in the United States. Gastroenterology. 2004, 127 (5 Suppl 1): S27-S34. 10.1053/j.gastro.2004.09.013.CrossRef
5.
Llovet JM, Burroughs A, Bruix J: Hepatocellular carcinoma. Lancet. 2003, 362: 1907-1917. 10.1016/S0140-6736(03)14964-1.CrossRef
6.
Wu L, Tang ZY, Li Y: Experimental models of hepatocellular carcinoma: developments and evolution. J Cancer Res Clin Oncol. 2009, 135: 969-981. 10.1007/s00432-009-0591-7.CrossRef
7.
Kudo M: Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology. 2008, 75 (Suppl 1): 1-12. 10.1159/000181865.CrossRef
8.
Llovet JM, Bruix J: Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol. 2008, 48: S20-S37. 10.1016/j.jhep.2008.01.022.CrossRef
9.
Qin LX, Tang ZY: Recent progress in predictive biomarkers for metastatic recurrence of human hepatocellular carcinoma: a review of the literature. J Cancer Res Clin Oncol. 2004, 130: 497-513. 10.1007/s00432-004-0572-9.CrossRef
10.
Tian J, Tang ZY, Ye SL, Liu YK, Lin ZY, Chen J, Xue Q: New human hepatocellular carcinoma (HCC) cell line with highly metastatic potential (MHCC97) and its expressions of the factors associated with metastasis. Br J Cancer. 1999, 81: 814-821. 10.1038/sj.bjc.6690769.CrossRef
11.
Li Y, Tang Y, Ye L, Liu YK, Chen J, Xue Q, Chen J, Gao DM, Bao WH: Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97. World J Gastroenterol. 2001, 7: 630-636.
12.
Li Y, Tang Y, Ye L, Liu B, Liu K, Chen J, Xue Q: Establishment of a hepatocellular carcinoma cell line with unique metastatic characteristics through in vivo selection and screening for metastasis-related genes through cDNA microarray. J Cancer Res Clin Oncol. 2003, 129: 43-51. 10.1007/s00432-003-0493-z.CrossRef
13.
Li Y, Tian B, Yang J, Zhao L, Wu X, Ye SL, Liu YK, Tang ZY: Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics. J Cancer Res Clin Oncol. 2004, 130: 460-468. 10.1007/s00432-004-0564-9.CrossRef
14.
Li Y, Tang ZY, Tian B, Ye SL, Qin LX, Xue Q, Sun RX: Serum CYFRA 21-1 level reflects hepatocellular carcinoma metastasis: study in nude mice model and clinical patients. J Cancer Res Clin Oncol. 2006, 132: 515-520. 10.1007/s00432-006-0098-4.CrossRef
15.
Ding SJ, Li Y, Tan YX, Jiang MR, Tian B, Liu YK, Shao XX, YE SL, Wu JR, Zeng R, Wang HY, Tang ZY, Xia QC: From proteomic analysis to clinical significance: overexpression of cytokeratin 19 correlates with hepatocellular carcinoma metastasis. Mol Cell Proteomics. 2004, 3: 73-81.CrossRef
16.
Albini A: Tumor microenvironment, a dangerous society leading to cancer metastasis. From mechanisms to therapy and prevention. Cancer Metastasis Rev. 2008, 27: 3-4. 10.1007/s10555-007-9102-y.CrossRef
17.
Fackler OT, Grosse R: Cell motility through plasma membrane blebbing. J Cell Biol. 2008, 181: 879-884. 10.1083/jcb.200802081.CrossRef
18.
de Hostos EL, Bradtke B, Lottspeich F, Guggenheim R, Gerisch G: Coronin, an actin binding protein of Dictyostelium discoideum localized to cell surface projections, has sequence similarities to G protein beta subunits. EMBO J. 1991, 10: 4097-4104.
19.
Uetrecht AC, Bear JE: Coronins: the return of the crown. Trends Cell Biol. 2006, 16: 421-426. 10.1016/j.tcb.2006.06.002.CrossRef
20.
Abelev GI, Perova SD, Khramkova NI, Postnikova ZA, Irlin IS: Production of embryonal alpha-globulin by transplantable mouse hepatomas. Transplantation. 1963, 1: 174-180.CrossRef
21.
Li D, Mallory T, Satomura S: Afp-l3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001, 313: 15-19. 10.1016/S0009-8981(01)00644-1.CrossRef
22.
Weitz IC, Liebman HA: Des-gamma-carboxy (abnormal) prothrombin and hepatocellular carcinoma: a critical review. Hepatology. 1993, 18: 990-997. 10.1002/hep.1840180434.CrossRef
23.
Deugnier Y, David V, Brissot P, Mabo P, Delamaire D, Messner M: Serum alpha-l-fucosidase: a new marker for the diagnosis of primary hepatic carcinoma?. Hepatology. 1984, 4: 889-892. 10.1002/hep.1840040516.CrossRef
24.
Hsu HC, Cheng W, Lai PL: Cloning and Expression of a Developmentally Regulated Transcript MXR7 in Hepatocellular Carcinoma: Biological Significance and Temporospatial Distribution. Cancer Res. 1997, 57: 5179-5184.
25.
Ito N, Kawata S, Tamura S, Takaishi K, Shirai Y, Kiso S: Elevated levels of transforming growth factor beta messenger RNA and its polypeptide in human hepatocellular carcinoma. Cancer Res. 1991, 51: 4080-4083.
26.
Cariani E, Lasserre C, Seurin D, Hamelin B, Kemeny F, Franco D: Differential Expression of Insulin-like Growth Factor II mRNA in Human Primary Liver Cancers, Benign Liver Tumors, and Liver Cirrhosis. Cancer Res. 1988, 48: 6844-6849.
27.
Ranke MB, Maier KP, Schweizer R, Stadler B, Schleicher S, Elmlinger MW: Pilot study of elevated levels of insulin-like growth factor-binding protein-2 as indicators of hepatocellular carcinoma. Horm Res. 2003, 60: 174-180. 10.1159/000073229.CrossRef
28.
Yoon SK, Lim NK, Ha SA, Park YG, Choi JY, Chung KW: The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res. 2004, 64: 5434-5441. 10.1158/0008-5472.CAN-03-3665.CrossRef
29.
Marrero JA, Romano PR, Nikolaeva O, Steel L, Mehta A, Fimmel CJ: Gp73, a resident golgi glycoprotein, is a novel serum marker for hepatocellular carcinoma. J Hepatol. 2005, 43: 1007-1012. 10.1016/j.jhep.2005.05.028.CrossRef
30.
Yamagamim H, Moriyama M, Matsumura H, Aoki H, Shimizu T, Saito T: Serum concentrations of human hepatocyte growth factor is a useful indicator for predicting the occurrence of hepatocellular carcinomas in c-viral chronic liver diseases. Cancer. 2002, 95: 824-834. 10.1002/cncr.10732.CrossRef
31.
Moriyama M, Matsumura H, Watanabe A, Nakamura H, Arakawa Y, Oshiro S: Detection of serum and intrahepatic KL-6 in anti-HCV positive patients with hepatocellular carcinoma. Hepatol Res. 2004, 30: 24-33. 10.1016/j.hepres.2004.04.007.CrossRef
32.
Semela D, Dufour JF: Angiogenesis and hepatocellular carcinoma. J Hepatol. 2004, 41: 864-880. 10.1016/j.jhep.2004.09.006.CrossRef
33.
Hann HW, Lee J, Bussard A, Liu C, Jin YR, Guha K: Preneoplastic markers of hepatitis B virus-associated hepatocellular carcinoma. Cancer Res. 2004, 64: 7329-7335. 10.1158/0008-5472.CAN-04-1095.CrossRef
34.
Hu WQ, Peng CW, Li Y: The expression and significance of P-glycoprotein, lung resistance protein and multidrug resistance-associated protein in gastric cancer. J Exp Clin Cancer Res. 2009, 28: 144-150. 10.1186/1756-9966-28-144.CrossRef
35.
Li W, Gomez E, Zhang Z: Immunohistochemical expression of stromal cell-derived factor-1 (SDF-1) and CXCR4 ligand receptor system in hepatocellular carcinoma. J Exp Clin Cancer Res. 2007, 26: 527-533.
36.
Li N, Long Y, Fan X, Liu H, Li C, Chen L, Wang Z: Proteomic analysis of differentially expressed proteins in hepatitis B virus-related hepatocellular carcinoma tissues. J Exp Clin Cancer Res. 2009, 28: 122-132. 10.1186/1756-9966-28-122.CrossRef
37.
Qiu FM, Yu JK, Chen YD, Jin QF, Sui MH, Huang J: Mining novel biomarkers for prognosis of gastric cancer with serum proteomics. J Exp Clin Cancer Res. 2009, 28: 126-133. 10.1186/1756-9966-28-126.CrossRef
38.
Rybakin V, Clemen CS: Coronin proteins as multifunctional regulators of the cytoskeleton and membrane trafficking. Bioessays. 2005, 27: 625-632. 10.1002/bies.20235.CrossRef
39.
Spoerl Z, Stumpf M, Noegel AA, Hasse A: Oligomerization, F-actin interaction, and membrane association of the ubiquitous mammalian coronin 3 are mediated by its carboxyl terminus. J Biol Chem. 2002, 277: 48858-48867. 10.1074/jbc.M205136200.CrossRef
40.
Thal D, Xavier CP, Rosentreter A, Linder S, Friedrichs B, Waha A, Pietsch T, Stumpf M, Noegel A, Clemen C: Expression of coronin-3 (coronin-1C) in diffuse gliomas is related to malignancy. J Pathol. 2008, 214: 415-424. 10.1002/path.2308.CrossRef
Metadata
Title
Coronin-1C is a novel biomarker for hepatocellular carcinoma invasive progression identified by proteomics analysis and clinical validation
Authors
Long Wu
Chun-Wei Peng
Jin-Xuan Hou
Yan-Hua Zhang
Chuang Chen
Liang-Dong Chen
Yan Li
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Journal of Experimental & Clinical Cancer Research / Issue 1/2010
Electronic ISSN: 1756-9966
DOI
https://doi.org/10.1186/1756-9966-29-17

Other articles of this Issue 1/2010

Journal of Experimental & Clinical Cancer Research 1/2010 Go to the issue

Research

Loss of heterozygosity and SOSTDC1 in adult and pediatric renal tumors

Research

Establishment of a new human pleomorphic malignant fibrous histiocytoma cell line, FU-MFH-2: molecular cytogenetic characterization by multicolor fluorescence in situ hybridization and comparative genomic hybridization

Review

Current implications of cyclophilins in human cancers

Research

A comparison of ARMS and DNA sequencing for mutation analysis in clinical biopsy samples

Research

A novel function for vimentin: the potential biomarker for predicting melanoma hematogenous metastasis

Research

Incidence of high chromogranin A serum levels in patients with non metastatic prostate adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits